Literature DB >> 29314442

LncRNA CDKN2BAS rs2157719 genetic variant contributes to medulloblastoma predisposition.

Yi-Dong Chen1, Nasha Zhang2, Xiao-Guang Qiu3, Jupeng Yuan2, Ming Yang2.   

Abstract

BACKGROUND: How germline single nucleotide polymorphisms are involved in the etiology of medulloblastoma remans poorly understood. We hypothesized that CCDKN2A/B rs1063192 and rs4977756 and also the long noncoding RNA (lncRNA) CDKN2BAS rs2157719 glioma susceptibility polymorphisms identified by genome-wide association studies may contribute to medulloblastoma predisposition.
METHODS: To test this hypothesis, we genotyped these genetic variants among 160 medulloblastoma patients and 443 health controls in a Chinese population. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by logistic regression.
RESULTS: We found that only the lncRNA CDKN2BAS rs2157719 T>C genetic polymorphism was significantly associated with an increased medulloblastoma risk (C allele: OR = 1.85, 95% CI = 1.32-2.58; p = 2.7 × 10-4 ). The stratified analyses showed an elevated risk of pediatric medulloblastoma associated with CDKN2BAS rs2157719 CC or TC genotype (both p < 0.05). Moreover, the association between the CDKN2BAS rs2157719 polymorphism and medulloblastoma risk is more pronounced in males (OR = 2.22, 95% CI = 1.36-3.62; p = 0.001).
CONCLUSIONS: The findings of the present study provide important insights into the genetic complexities and predisposition of medulloblastoma in Chinese, especially at the lncRNA germline variation level.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  CDKN2BAS; genetic polymorphism; glioma; long non-coding RNA; medulloblastoma; single nucleotide polymorphism; susceptibility

Mesh:

Substances:

Year:  2018        PMID: 29314442     DOI: 10.1002/jgm.3000

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  6 in total

Review 1.  Risk factors for childhood and adult primary brain tumors.

Authors:  Quinn T Ostrom; Maral Adel Fahmideh; David J Cote; Ivo S Muskens; Jeremy M Schraw; Michael E Scheurer; Melissa L Bondy
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

2.  LncRNA CDKN2BAS predicts poor prognosis in patients with hepatocellular carcinoma and promotes metastasis via the miR-153-5p/ARHGAP18 signaling axis.

Authors:  Junzheng Chen; Xitian Huang; Weijun Wang; Hongcheng Xie; Jianfeng Li; Zhenfen Hu; Zhijian Zheng; Huiyong Li; Lingfang Teng
Journal:  Aging (Albany NY)       Date:  2018-11-29       Impact factor: 5.682

Review 3.  SNPs and Somatic Mutation on Long Non-Coding RNA: New Frontier in the Cancer Studies?

Authors:  Linda Minotti; Chiara Agnoletto; Federica Baldassari; Fabio Corrà; Stefano Volinia
Journal:  High Throughput       Date:  2018-11-16

Review 4.  The Non-coding Side of Medulloblastoma.

Authors:  Pietro Laneve; Elisa Caffarelli
Journal:  Front Cell Dev Biol       Date:  2020-05-27

5.  LncRNA-Associated Genetic Etiologies Are Shared between Type 2 Diabetes and Cancers in the UAE Population.

Authors:  Roberta Giordo; Rida Gulsha; Sarah Kalla; George A Calin; Leonard Lipovich
Journal:  Cancers (Basel)       Date:  2022-07-07       Impact factor: 6.575

6.  Methylation Profiling of Medulloblastoma in a Clinical Setting Permits Sub-classification and Reveals New Outcome Predictions.

Authors:  Musa Alharbi; Nahla Mobark; Yara Bashawri; Leen Abu Safieh; Albandary Alowayn; Rasha Aljelaify; Mariam AlSaeed; Amal Almutairi; Fatimah Alqubaishi; Ebtehal AlSolme; Maqsood Ahmad; Ayman Al-Banyan; Fahad E Alotabi; Jonathan Serrano; Matija Snuderl; May Al-Rashed; Malak Abedalthagafi
Journal:  Front Neurol       Date:  2020-03-20       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.